Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
GALECTIN THERAPEUTICS INC (GALT) Stock Price & Overview
NASDAQ:GALT • US3632252025
Current stock price
2.27 USD
0 (0%)
At close:
2.27 USD
0 (0%)
After Hours:
The current stock price of GALT is 2.27 USD. Today GALT is down by 0%. In the past month the price decreased by -14.98%. In the past year, price increased by 63.31%.
GALT Key Statistics
52-Week Range1.21 - 7.13
Current GALT stock price positioned within its 52-week range.
1-Month Range2.18 - 2.77
Current GALT stock price positioned within its 1-month range.
- Market Cap
- 149.434M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.48
- Dividend Yield
- N/A
GALT Stock Performance
Today
0%
1 Week
-2.58%
1 Month
-14.98%
3 Months
-19.79%
Longer-term
6 Months -60.93%
1 Year +63.31%
2 Years -16.54%
3 Years +44.59%
5 Years -42.82%
10 Years +53.38%
GALT Stock Chart
GALT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GALT. When comparing the yearly performance of all stocks, GALT is one of the better performing stocks in the market, outperforming 77.93% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
GALT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to GALT. GALT may be in some trouble as it scores bad on both profitability and health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
GALT Earnings
Next Earnings DateMay 18, 2026
Last Earnings DateMar 31, 2026
PeriodQ4 / 2025
EPS Reported-$0.08
Revenue Reported
EPS Surprise 21.57%
Revenue Surprise %
GALT Forecast & Estimates
7 analysts have analysed GALT and the average price target is 11.22 USD. This implies a price increase of 394.27% is expected in the next year compared to the current price of 2.27.
Analysts
Analysts82.86
Price Target11.22 (394.27%)
EPS Next Y34.13%
Revenue Next YearN/A
GALT Index Membership
GALT is currently included in the following stock indexes tracked on ChartMill.
GALT Financial Highlights
Over the last trailing twelve months GALT reported a non-GAAP Earnings per Share(EPS) of -0.48. The EPS increased by 36.84% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-30.97M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -158.58% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%57.89%
Sales Q2Q%N/A
EPS 1Y (TTM)36.84%
Revenue 1Y (TTM)N/A
GALT Ownership
Ownership
Inst Owners17.65%
Shares65.83M
Float46.67M
Ins Owners18.89%
Short Float %15.99%
Short Ratio22.87
GALT Industry Overview
GALT operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
GALT Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GALT
Company Profile
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. The company is headquartered in Norcross, Georgia and currently employs 15 full-time employees. The company went IPO on 2002-09-04. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The firm's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
Company Info
IPO: 2002-09-04
GALECTIN THERAPEUTICS INC
Suite 240, 4960 Peachtree Industrial Boulevard
Norcross GEORGIA 30071 US
CEO: Joel Lewis
Employees: 15
Phone: 16786203186
GALECTIN THERAPEUTICS INC / GALT FAQ
What does GALT do?
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. The company is headquartered in Norcross, Georgia and currently employs 15 full-time employees. The company went IPO on 2002-09-04. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The firm's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
What is the current price of GALT stock?
The current stock price of GALT is 2.27 USD.
Does GALT stock pay dividends?
GALT does not pay a dividend.
What is the ChartMill rating of GALECTIN THERAPEUTICS INC stock?
GALT has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does GALECTIN THERAPEUTICS INC belong to?
GALECTIN THERAPEUTICS INC (GALT) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of GALT stock?
GALECTIN THERAPEUTICS INC (GALT) has a market capitalization of 149.43M USD. This makes GALT a Micro Cap stock.
Can you provide the upcoming earnings date for GALECTIN THERAPEUTICS INC?
GALECTIN THERAPEUTICS INC (GALT) will report earnings on 2026-05-18.